A photo of Lara Danziger-Isakov.

Lara A. Danziger-Isakov, MD, MPH


  • Director, Immunocompromised Host Infectious Disease
  • Professor, UC Department of Pediatrics

About

Biography

Children are remarkably resilient, and I find it gratifying to help them live to their full potential despite life-threatening illness. The unanswered questions these patients present drive my research interests — and, as a result, my research is constantly evolving.

I focus on better understanding the infection risk in immunocompromised patients. My research includes discovering new methods to quickly diagnose infection and evaluating the most appropriate treatment options specific to a pathogen. I also study the noninfectious complications and the consequences of infections related to a patient’s underlying illness.

I specialize in treating infections for a variety of patient populations, including those who have received solid organ transplants and hematopoietic stem cell transplants (HSCT), immunocompromised patients and patients undergoing treatment for various cancers. Many of the infections I study are viral or fungal in nature.

My research focuses on understanding the impact of host-pathogen interactions. I have been the protocol chair for three clinical trials supported by the National Institute of Allergy and Infectious Diseases (NIAID). These trials evaluated how the immune system responds to infection and, later, how that impacts graft survival in pediatric transplantation. They also examined the impact of B-cell induction and the barriers to treatment adherence. In the Studies in Pediatric Liver Transplantation (SPLIT) study, I act as principle investigator for the evaluation of cytomegalovirus (CMV) prophylaxis.

I also research infectious disease epidemiology and risk factors, as well as immunization safety and efficacy in immunocompromised pediatric patients. This includes my role as principle investigator for an ongoing multicenter study of live viral vaccination after solid organ transplantation.

As a result of my work, I received the 2012 American Society of Transplantation Clinical Science Career Development Award. I have served as a board member, secretary, annual meeting program chair and, most recently, president-elect for the International Society of Heart and Lung Transplantation.

I am the past chair for the Infectious Disease Community of Practice (IDCOP) for the American Society of Transplantation. And from 2018-2020, I worked as the deputy editor of the American Journal of Transplantation.

MD: Case Western Reserve University, Cleveland, OH, 1997.

MPH: Saint Louis University, St. Louis, MO, 2004.

Residency: Pediatrics, Cleveland Clinic Foundation, Cleveland, OH, 1997-2000.

Fellowship: Pediatric Infectious Diseases, St. Louis Children’s Hospital, Washington Univeristy, St. Louis, MO, 2000-2003.

Certification: Pediatrics, 2000; Pediatric Infectious Diseases, 2003.

Interests

Pediatric infectious disease; infections in transplantation; infections in immunocompromised hosts

Services and Specialties

Infectious Diseases, Lung Transplant

Interests

Infections in transplantation; infections in immunocompromised hosts

Research Areas

Infectious Diseases

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

The IPTA Nashville consensus conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: II-consensus guidelines for prevention. Green, M; Squires, JE; Chinnock, RE; Comoli, P; Danziger-Isakov, L; Dulek, DE; Esquivel, CO; Höcker, B; L'Huillier, AG; Mazariegos, GV; et al. Pediatric Transplantation. 2024; 28:e14350.

The IPTA Nashville Consensus Conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: III - Consensus guidelines for Epstein-Barr virus load and other biomarker monitoring. Preiksaitis, J; Allen, U; Bollard, CM; Dharnidharka, VR; Dulek, DE; Green, M; Martinez, OM; Metes, DM; Michaels, MG; Smets, F; et al. Pediatric Transplantation. 2024; 28:e14471.

The Durability of Antibody Responses of Two Doses of High-Dose Relative to Two Doses of Standard-Dose Inactivated Influenza Vaccine in Pediatric Hematopoietic Cell Transplant Recipients: A Multi-Center Randomized Controlled Trial. Schuster, JE; Hamdan, L; Dulek, DE; Kitko, CL; Batarseh, E; Haddadin, Z; Stewart, LS; Stahl, A; Potter, M; Rahman, H; et al. Clinical Infectious Diseases. 2024; 78:217-226.

Body surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients. Demirhan, S; Munoz, FM; Valencia Deray, KG; Bocchini, CE; Danziger-Isakov, L; Blum, S; Sharma, TS; Sherman, G; Boguniewicz, J; Bacon, S; et al. American Journal of Transplantation. 2023; 23:1961-1971.

A review of transplant infectious diseases and pediatric transplant infectious diseases curriculum. Morales, MK; Danziger-Isakov, L; Nematollahi, S. Current Opinion in Organ Transplantation. 2023; 28:463-470.

1453. Whole Genome Sequencing: A Useful Tool in a VRE Outbreak Among Immunocompromised Pediatric Patients. Murphy, CR; Mahulkar, S; Griffin, G; Griffin, C; Ankrum, AL; Otto, WR; Danziger-Isakov, LA; Haslam, D; Scaggs-Huang, F. Open Forum Infectious Diseases. 2023; 10:ofad500.1290.

1702. Disseminated Candidiasis after Candidemia: Epidemiology, Diagnostic Evaluation, and Risk Factors. Whitehurst, D; Murphy, CR; Teoh, Z; Brammer, CN; Perkins, K; Paulsen, GC; Danziger-Isakov, LA; Miller-Handley, H; Otto, WR. Open Forum Infectious Diseases. 2023; 10:ofad500.1535.

Immunogenicity and Safety of Alternative Influenza Vaccination Strategies in Repeated Seasons in Pediatric Hematopoietic-Cell Transplant Recipients. Bahakel, H; Spieker, AJ; Stahl, A; Rahman, H; Amarin, J; Hamdan, L; Dulek, DE; Kitko, CL; Batarseh, E; Haddadin, Z; et al. Journal of the Pediatric Infectious Diseases Society. 2023; 12:s21.

Body Surface Area Valganciclovir Prophylactic Dosing is Associated with a Higher Rate of Drug-Associated Toxicities Compared to Body Weight Dosing in Pediatric Solid Organ Transplant Recipients. Demirhan, S; Munoz, FM; Valencia Deray, KG; Bocchini, CE; Danziger-Isakov, L; Blum, S; Sharma, TS; Sherman, G; Boguniewicz, J; Bacon, S; et al. Journal of the Pediatric Infectious Diseases Society. 2023; 12:s23.

Balancing the live virus vaccine scales: Protection vs risk. Posfay-Barbe, KM; Danziger-Isakov, L. American Journal of Transplantation. 2023; 23:1659-1660.

From the Blog

Live Vaccinations Appear Safe for Organ Transplant Recipients
Infectious Diseases and Vaccines

Live Vaccinations Appear Safe for Organ Transplant Recipients

Lara A. Danziger-Isakov, MD, MPH10/16/2023

Hepatitis of Unknown Origin in Kids: What Do We Know?
Blog Rare and Complex Conditions

Hepatitis of Unknown Origin in Kids: What Do We Know?

By Lara Danziger-Isakov, MD10/6/2022

The COVID-19 Vaccine and Immunocompromised Kids
Blog Vaccines

The COVID-19 Vaccine and Immunocompromised Kids

By Lara Danziger-Isakov, MD11/22/2021

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

4.6
Overall Patient Rating